Background. Information on measles vaccine effectiveness (VE) is critical to help inform policies for future global measles control goals.
The successful isolation of measles virus in 1954 by Enders and Peebles marked the eve of research that in the early 1960s resulted in availability of the first live attenuated measles-containing vaccines (MCVs). In 1963, the live attenuated MCV (Edmonston B strain) became licensed in the United States, and 2 additional attenuated live MCVs derived from the Edmonston strain became available in 1965 (Schwartz strain) and in 1968 (Moraten strain) [1] . The Moraten strain is currently the only MCV used in the United States; internationally, the most frequently used MCVs are of the Schwartz or the Edmonston-Zagreb strain and 2 other attenuated MCV strains derived from the original Edmonston strain [1] . Several other attenuated MCVs used in international settings are not related to the Edmonston strain, but are rather produced from locally derived wild-type measles virus strains; examples include the Leningrad-16 strain (Russian Federation), the Shanghai-191 strain (People's Republic of China), and CAM-70 and AIK-C strains (Japan) [1] .
Serologic evaluations have demonstrated that, when handled and administered under ideal conditions, currently used attenuated MCVs elicit immune responses in the large majority of susceptible vaccine recipients. Age at vaccination is one of the key host-related determinants of vaccine efficacy as measured by antibody response after vaccination: frequently cited figures are that 85% of children develop protective antibody levels when given 1 dose of MCV at 9 months of age, whereas 90%-95% respond when vaccinated at 12 months [2, 3] . Other hostrelated factors that may adversely affect immune response after measles vaccination include presence of passively acquired measles antibody, immunologic immaturity at vaccination, infection with human immunodeficiency virus type 1 (HIV-1), other immunosuppressive conditions, and in some circumstances, concurrent acute infections [3] .
Routine measles vaccination remained sporadic in developing countries until the advent of the World Health Organization (WHO) Expanded Programme on Immunization (EPI) during the late 1970s. In 1983, the WHO EPI recommended routine vaccination with a single dose of MCV for children aged $9 months [1] . Most developing countries subsequently adopted that recommendation into their national immunization schedule and MCV use became more widespread, with single-dose measles vaccination programs remaining the standard practice in most parts of the world for almost 2 decades.
Measles-containing vaccines are generally recognized as safe and effective [1] . In 2005, .1 decade after the successful elimination of the indigenous measles virus circulation in Finland through a 2-dose routine vaccination program [4] and 3 years after region-wide measles elimination in the Americas [5] , the WHO Global Immunization Vision and Strategy document established a goal of 90% global measles mortality reduction by 2010, compared with 2000 estimates [6] . Until 2009, strategies emphasized routine 1-dose vaccination and the second opportunity for vaccination mainly through Supplemental Immunization Activities (SIAs), primarily to reach previously unvaccinated children. During 2000-2008, these efforts resulted in a 78% decrease in estimated measles-related deaths worldwide, from an estimated 733,000 deaths in 2000 to 164,000 deaths in 2008 [7] . In 2009, a global recommendation was made for a 2-dose MCV scheduled for all children [8] . Currently, 5 of the 6 WHO Regions have established target dates for measles elimination, and the feasibility of a global eradication goal is being evaluated [9, 10]. As more ambitious measles control targets are being considered, we present here results of a literature review undertaken to summarize experience with effectiveness of measles-containing vaccines administered at different ages worldwide, to inform the formulation of future vaccination policies.
METHODS

Identification of Studies
Medline and PubMed were searched for articles on measlescontaining vaccine effectiveness (VE), applying different combinations of the terms ''measles,'' in conjunction with ''vaccine,'' ''mumps, rubella vaccine,'' ''outbreak,'' ''effectiveness,'' ''efficacy,'' and ''vaccine failure.'' Any additional articles that may not have been included in the initial search strategy were identified by reviewing references of articles obtained and the Vaccines textbook (5 th edition) [1] .
Inclusion Criteria
We considered any reports that provided estimates of measlescontaining VE that were available in the English language since vaccine licensure in 1963 until May 2010. We included only articles that evaluated the effectiveness of measles-containing vaccines administered under routine field conditions by estimating the VE using $1 methods described by Orenstein et al [11] .
Data Extraction and Statistical Analyses
We abstracted data from each article that included (but was not limited to) the following key variables: year and type of study (ie cohort, case-control, or screening method), country and WHO Region, ages that were assessed and their birth cohorts, age at first and second dose of vaccine, vaccine type and strain (when available), VE point estimate, and VE 95% confidence intervals (CIs; when available). VE point estimates for the overall study sample (where provided) were assessed, as were estimates stratified by age of receipt of the first dose of a measles-containing vaccine at 9-11 months of age and at $12 months of age. A specific article may include several point estimates because of assessments of VE for different age groups. Some articles presented an overall VE point estimate for all ages considered in the study and separate VE point estimates for $2 age strata in the same study group. Furthermore, a number of articles presented VE estimates resulting from .1 study type, including cohort, case-control, and screening studies. In such situations, each of the VE point estimates was separately included in the summary table along with the explanatory information.
We explored the distribution of the published VE estimates by age of vaccination and by geographic region on a subset of the VE point estimates produced by case-control or cohort studies included in this review. ). Finally, we separately summarized the distribution of the published VE estimates by age of vaccination for VE estimates produced by case-control or cohort studies in which case patients had either laboratory confirmed measles, or in which cases were epidemiologically linked to a laboratoryconfirmed outbreak and in which vaccination status for all study participants was ascertained using a written vaccination record. All summary statistics for the aforementioned analyses were calculated using JMP Software (SAS Institute).
We did not include point estimates that were only speculated in some of the articles as an attempt to address possible study biases (eg, possible misclassification based on vaccination status, disease, and susceptibility status). VE estimates that included children who received vaccine at #8 months of age were not included, because this is not a routinely recommended age for measles vaccination [3, 12] . [16] , multiple live further attenuated strains [1] , and unspecified [2] ).
RESULTS
Overall
To assess whether some factors related with the period during that the study was conducted may have influenced the VE estimates, we explored the distribution of MCV1 VE point estimates by grouping them into 2 intervals (1969-1989 and 1990-2009) Distribution of the reported MCV1 VE by age of vaccination was explored taking into consideration 106 nonnegative MCV1 VE point estimates reported from studies with case-control or cohort designs (Table 2) . When MCV1 was administered at any age $9 months, the median reported VE was 91.0% (IQR, 79.0%-95.0%; range, 25.0%-100.0%). When MCV1 was administered at age 9-11 months, the median reported VE was 77.0% (IQR, 68.0%-91.0%); by WHO region, the median MCV1 VE point estimates ranged from 73.0% in AFR to 96.0% in EUR. The median VE for MCV1 given at .12 months was 92.0% (IQR, 88.0%-96.0%); by region, it ranged from 88% in AFR to 94% in AMR and SEAR (Table 2) .
When the analysis was restricted to include only the 44 MCV1 VE estimates from those case-control or cohort studies in which the vaccination status for all study participants was ascertained using an official record and in which laboratory confirmation was used to confirm measles diagnosis among case patients participating in the study or the outbreaks with which these cases were epidemiologically associated, the median VE of MCV1 given at age 9-11 months was 84.0% (IQR, 72.0%-95.0%), at age $12 months was 92.5% (IQR, 84.8%-97.0%), and at any age $9 months was 92.0% (IQR, 84.0%-96.8%; Table 2 
Two-Dose MCV VE
Overall, in the 71 articles reviewed, we identified 14 VE point estimates that presented information on MCV2, representing AMR (n 5 6), EUR (n 5 6), and WPR (n 5 2) (This excludes 1 point estimate from a study in which methodology did not meet the inclusion criteria for this review). Nine of the 14 MCV2 VE point estimates were from an unspecified type vaccine and vaccine strain, 2 were from a live further attenuated strain, and 1 each of Schwarz and Moraten.
We identified 8 case-control or cohort studies that evaluated MCV2 VE, compared with no vaccination [40, 44, 55, 58, 59, 60, 79, 82] ; on the basis of these studies, the overall median VE of receipt of MCV2, compared with no vaccination, was 94.1% (IQR, 88.3%-98.3%).
We identified 5 case-control or cohort studies that evaluated the effectiveness of MCV2, compared with receipt of MCV1; one study reported an incremental VE of 67% [44] , and the other 4 reported MCV2 VE point estimates of 94%-100% [4, 42, 45, 61] .
DISCUSSION
Results of this literature review suggest that the VE of MCV1 administered at 9-11 months of age is generally lower than 85%, which is the usual expected rate of immune response after vaccination at that age [3] . In contrast, effectiveness of MCV1 administered at age of $12 months is close to the usually cited values of 90%-95% [3] . Published MCV1 effectiveness estimates vary by geographic region, which may be related to the age of vaccination and other factors. Lower i This study also reported separate values for vaccine effectiveness at 9 months (26%) and at .9 months (72%) j Live further attenuated than expected VE estimates were primarily reported by studies conducted in countries belonging to the African and the South-East Asian regions of the WHO, where MCV1 is usually scheduled for children aged $9 months of age.
In contrast, studies conducted in the American, European, and Western Pacific regions, where countries more frequently recommend MCV1 at $12 months of age, more frequently documented higher VE estimates. There was little difference in distribution of published MCV1 VE point estimates with regard to the period during which the study was conducted that would suggest that more recent VE estimates may be generally higher than the historic VE estimates because of factors, such as programmatic improvements related to efforts to strengthen immunization infrastructure (eg, better cold chain and better vaccine handling), or because of certain host factors, such as younger age of loss of maternal antibody in children born to vaccinated mothers [85] . The retrospective nature of VE evaluation studies often precludes precise identification of the reasons for reduced effectiveness. Generally, the reasons related to low VE estimates can be grouped into 3 broad categories, including (1) issues related to study methods; (2) program-related factors, such as appropriate vaccine storage, handling, and administration; and (3) host-related factors, most notably, age at vaccination.
Previously described reasons that could result in biasing the VE estimates and that are inherent to study methods include misclassification of case status because of inaccurate diagnosis, misclassification of the vaccination status, and lack of comparability between the cases and the noncases considered in the VE evaluation study with regard to potential confounding factors (eg, differences in risk of exposure to measles during the outbreak and differences in susceptibility to measles because of an unaccounted history of infection) [11] . Several articles included in this review acknowledge that $1 of these reasons may have led to an underestimate of the VE, including possible issues with misclassification of the disease status [14, 21, 24] , misclassification of vaccination status [34, 80, 81] , and bias resulting from possible differences among study participants in risk for measles infection because of inability to ascertain history of measles disease [17] . One study identified the small number of cases as a potential reason for a low VE point estimate in the cohort study that evaluated VE for children aged 9-11 months; a case-control analysis undertaken in the same study population yielded a VE in the expected range [18] .
Program-related factors were most frequently hypothesized as possible reasons for low reported VE estimates. These included cold chain issues [15, 19, 25, 26, 62, 69, 70] , inadequate vaccine handling [25, 69] , poor vaccine storage [71, 81] , and inadequate vaccine administration [71] . However, only one study reported actual observed programmatic reasons that may have resulted in low VE; these reasons included inadequate vaccination practices and frequent power cuts that may have compromised cold chain [14] .
A number of authors discussed various host factors that may have been related to lower MCV1 VE estimates reported in their studies, including young age at vaccination with MCV1 and subsequent interference from maternally derived measles IgG antibodies [15, 47, 62, 67] , malnutrition [67] , and HIV infection [26, 27] .
Waning immunity was considered as a possible explanation for a low MCV1 VE point estimate in 1 of the 3 age strata considered in one study, but it was not found to be a probable explanation for the low VE estimate because it was not coupled with a high attack rate among vaccinated children [33] and because both waning immunity and primary vaccine failure were discussed in 2 separate studies conducted in India as possible reasons for low MCV1 VE [65, 67] . However, no evidence of waning immunity was found in studies that investigated large outbreaks in island populations that occurred after long intervals without documented measles virus circulation [77, 82] .
Intensity of exposure resulting from crowding was recognized as a possible reason for reduced MCV1 VE in 2 studies that reported low MCV1 VE [24, 38] . Crowding also may have been a factor for observed lower VE in other settings. In a study conducted during a large measles outbreak in a boarding school, Yeung et al [46] documented an apparently lower 2-dose VE among students who received both doses outside the United States (94%; 95% CI, 69.6%-98.3%) than among those who received both doses in the United States (99.1%; 95% CI, 95.5%-98.8%); the authors hypothesized that the reasons for this apparent difference may include the cold chain, mishandling of vaccine with respect to constitution, less accurate vaccination histories, or greater intensity of exposure during the outbreak.
The results from 14 studies that presented two-dose VE estimates indicate that in general, two doses of vaccine provide excellent protection against measles. However, three of eight MCV2 VE point estimates in which effectiveness of 2-dose vaccination was compared with no vaccination yielded an MCV2 estimate of ,90%. All three of these studies also reported reduced MCV1 VE point estimates, but possible reasons for such results were not discussed [44, 58, 79] .
The results of this literature review are subject to at least 4 broad categories of limitations. First, our search was limited to published English-language studies and did not consider an unknown number of publications in other languages. Second, because our review focused on published results only, it is also possible that our results are subject to publication bias; unpublished studies may have yielded results different from those that were published. Third, the review included observational study results with numerous limitations inherent to study design, varying degrees of completeness and quality of presented data, and an uneven distribution of studies between and in geographic regions. A concerted effort was made to tabulate the original VE estimates as reported in the source articles, to convey, at least in part, the diversity of the included studies. Finally, we were able to identify relatively few studies that evaluated MCV2 VE.
The small number of published studies that evaluated MCV2 VE may be at least partly related to a small number of measles outbreaks among vaccinated individuals in areas with mature 2-dose vaccination programs. Indeed, sustained high 2-dose measles vaccination coverage was documented as the key strategy in achieving and sustaining measles elimination in Finland [4] , the United States [85] , and throughout the the Americas [5] . Postelimination measles outbreaks in these settings have mainly been associated with gaps in vaccine-induced immunity in select communities, which is a finding that usually precludes a need for VE evaluation [86] [87] [88] . In contrast, during 2000-2010, some countries that were formerly a part of the Soviet Union experienced large measles outbreaks among adolescents and adults in spite of mature 2-dose vaccination programs and high reported vaccination coverage since the early 1980s; this raised concerns about both accuracy of the historic vaccination records and VE [55, 56] .
Since 2009, the WHO has recommended two doses of MCV for all children [8] . As more advanced global, regional, and national measles control goals are being considered, increasing use of measles-containing vaccine should be anticipated to result not only in decreasing disease incidence but also in a greater proportion of vaccinated individuals among cases in future measles outbreaks [11] . Therefore, further efforts will be needed to encourage investigation of outbreaks, including VE evaluations. As vaccination efforts continue to be scaled up globally, VE evaluations will be critical to maintain confidence in vaccination programs and to quickly identify any subpopulations and settings where certain host-or program-related factors may be b Includes point estimates in 9-11 months and $12 months categories, and those which do not fall within the 9-11 months and $12 months distinct categories leading to reduced VE. Measles outbreaks occurring in settings with high prevalence of HIV infection and AIDS deserve particular attention for future VE evaluations because of previously recognized issues with lower vaccine immunogenicity and uncertainties about duration of vaccine-derived immunity in HIVinfected children [3] . In summary, published VE studies indicate the importance of recommending 2 doses of measles vaccine to achieve and sustain the measles mortality reduction and regional elimination goals. To ensure appropriate monitoring of measles VE in areas that have been traditionally underrepresented in the published literature, such as the African, SouthEast Asian, and Eastern Mediterranean Regions, further efforts are needed to support capacity building for epidemiologic investigation of measles outbreaks, scale up laboratory support for measles diagnostics and surveillance, and increase availability and reliability of written vaccination records.
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